Topoisomerase inhibitors: Pharmacology and emerging nanoscale delivery systems.
Cancer
Chemotherapy
Drug delivery systems
Nanocarriers
Nanoparticles
Topoisomerase inhibitors
Journal
Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
09
10
2019
revised:
11
11
2019
accepted:
16
11
2019
pubmed:
20
11
2019
medline:
6
1
2021
entrez:
20
11
2019
Statut:
ppublish
Résumé
Topoisomerase enzymes have shown unique roles in replication and transcription. These enzymes which were initially found in Escherichia coli have attracted considerable attention as target molecules for cancer therapy. Nowadays, there are several topoisomerase inhibitors in the market to treat or at least control the progression of cancer. However, significant toxicity, low solubility and poor pharmacokinetic properties have limited their wide application and these characteristics need to be improved. Nano-delivery systems have provided an opportunity to modify the intrinsic properties of molecules and also to transfer the toxic agent to the target tissues. These delivery systems leads to the re-introduction of existing molecules present in the market as novel therapeutic agents with different physicochemical and pharmacokinetic properties. This review focusses on a variety of nano-delivery vehicles used for the improvement of pharmacological properties of topoisomerase inhibitors and thus enabling their potential application as novel drugs in the market.
Identifiants
pubmed: 31743776
pii: S1043-6618(19)32219-4
doi: 10.1016/j.phrs.2019.104551
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Topoisomerase Inhibitors
0
DNA Topoisomerases
EC 5.99.1.-
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
104551Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.